ATC code L02

ATC code L: Antineoplastic and immunomodulating agents
Other ATC codes

ATC code L02 Endocrine therapy is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup L02 is part of the anatomical group L Antineoplastic and immunomodulating agents.[4]

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL02.[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

  1. ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
  2. ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
  3. ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
  4. ^ "ATC/DDD Index 2022: code L02". WHO Collaborating Centre for Drug Statistics Methodology.
  5. ^ "ATCvet Index 2022: code QL02". WHO Collaborating Centre for Drug Statistics Methodology.